TY - JOUR
T1 - Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
AU - Garber, Alan J.
AU - Donovan, Daniel S.
AU - Dandona, Paresh
AU - Bruce, Simon
AU - Park, Jong Soon
N1 - Funding Information:
Originally received: June 21,1993. Revision accepted: June 17, 1994. * Members of the Herpetic Eye Disease Study are listed in the Appendix at the end of this article. Presented in part at the American Academy of Ophthalmology Annual Meeting, Dallas, November 1992. Supported in part by cooperative agreements (EY07479, EY07480, EY07482, EY07483, EY07486, EY07487, EY07488, EY07489, and EY07496) with the National Eye Institute, National Institutes of Health, and the United States Department of Health and Human Services, Bethesda, Maryland. IOLAB Corporation and Burroughs Well come Co. supplied the study medications. The authors have no proprietary interest in any of the drugs or devices used in this study. Reprint requests to Chandler R. Dawson, MD, Francis I. Proctor Foundation, University of Califomia, San Francisco, San Francisco, CA 94143-0412.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Association's recommended treatment goal of glycosylated hemoglobin levels. This multicenter, double-blind trial enrolled patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A1C (A1C), >7% and <12%) with diet and exercise alone to compare the benefits of initial therapy with glyburide/metformin tablets vs. metformin or glyburide monotherapy. Patients (n = 486) were randomized to receive glyburide/metformin tablets (1.25/250 mg), metformin (500 mg), or glyburide (2.5 mg). Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body weight, and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment. Glyburide/metformin tablets caused a superior mean reduction in A1C from baseline (-2.27%) vs. metformin (-1.53%) and glyburide (-1.90%) monotherapy (P = 0.0003). Glyburide/metformin also significantly reduced fasting plasma glucose and 2-h postprandial glucose values compared with either monotherapy. The final mean doses of glyburide/metformin (3.7/735 mg) were lower than those of metformin (1796 mg) and glyburide (7.6 mg). First-line treatment with glyburide/metformin tablets provided superior glycemic control over component monotherapy, allowing more patients to achieve American Diabetes Association treatment goals with lower component doses in drug-naive patients with type 2 diabetes.
AB - Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Association's recommended treatment goal of glycosylated hemoglobin levels. This multicenter, double-blind trial enrolled patients with type 2 diabetes who had inadequate glycemic control [glycosylated hemoglobin A1C (A1C), >7% and <12%) with diet and exercise alone to compare the benefits of initial therapy with glyburide/metformin tablets vs. metformin or glyburide monotherapy. Patients (n = 486) were randomized to receive glyburide/metformin tablets (1.25/250 mg), metformin (500 mg), or glyburide (2.5 mg). Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body weight, and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment. Glyburide/metformin tablets caused a superior mean reduction in A1C from baseline (-2.27%) vs. metformin (-1.53%) and glyburide (-1.90%) monotherapy (P = 0.0003). Glyburide/metformin also significantly reduced fasting plasma glucose and 2-h postprandial glucose values compared with either monotherapy. The final mean doses of glyburide/metformin (3.7/735 mg) were lower than those of metformin (1796 mg) and glyburide (7.6 mg). First-line treatment with glyburide/metformin tablets provided superior glycemic control over component monotherapy, allowing more patients to achieve American Diabetes Association treatment goals with lower component doses in drug-naive patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0043132411&partnerID=8YFLogxK
U2 - 10.1210/jc.2002-021225
DO - 10.1210/jc.2002-021225
M3 - Article
C2 - 12915642
AN - SCOPUS:0043132411
SN - 0021-972X
VL - 88
SP - 3598
EP - 3604
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 8
ER -